The global transplantation market is expected to grow at a CAGR of 9.5% during forecast period 2020 to 2027 and projected to hit around USD 27.07 billion by 2027. The global transplantation market was valued at USD 13.10 billion in 2019.

Rising demand for the organ transplantation to treat organ failure and novel tissue transplantation products is the prime factor that drives the market growth.

Organ failure occurs because of various factors that include loss of blood, serious trauma, drug abuse, poisoning, sepsis, leukemia, and other acute diseases. Demand for organ and tissue transplantation mainly heart, kidney, lungs, and liver is very high. Alcohol consumption, unhealthy dietary habits, drug abuse, and lack of exercise are some of the major causes of organ failure. This expected to trigger the demand for transplantation products in the coming years. Additionally, increasing number of acute diseases has also resulted in the rising cases of organ failure.

Transplantation Market Size & Market Analysis

However, customary and religious belief along with lack of awareness related to organ donation prevents large number of people from donating organs. Thus, shortage of organs for the treatment of organ transplantation is likely to hinder the market growth. There is a massive gap between the supply and demand of organ for the treatment of organ failure. As per the U.S. Department of Health & Human Services report in 2019, total number of patients for kidney transplantation was 43,201, yet only 23,401 procedures for kidney transplantation were performed.

Product Type Insights

Tissue product segment was the highest revenue contributor in the global transplantation market in 2019, accounting for a market value share of nearly 58%. Significant rise in the transplantation procedures such as heart valves, cochlear, orthopedic soft tissues, and bone marrow prominently drives the growth of the segment. Further, advancement and development of new transplantation products is the other most important factor that propels the market growth. For instance, in September 2015, Arthrex Inc. introduced ArthroFlexAcellular Dermal Matrix, an orthobiologic product that is generally used capsular reconstruction.

On the other hand, immunosuppressive drugs segment projected to exhibit the fastest growth during the forecast period. This is mainly attributed to the increasing use of these drugs to prevent the post-transplant organ or tissue rejection. Rising number of chronic diseases has significantly boosted the organ transplantation market, which in turn expected to fuel the growth for immunosuppressive drugs over the analysis period.

Application Insights

Tissue transplantation application segment emerged as the global leader in the global transplantation market, with a revenue share of around 60% in the year 2019 and projected to expand at the fastest rate during the forecast period. This is attributed to the fact that replacement of cornea, skin, heart valves, bones, nerves, tendons, and veinsare the most common procedures performed globally. Furthermore, the increasing cases of burn and accidents expected to fuel the demand for tissue products in the coming years.

Besides this, organ transplantation analyzed to exhibit significant growth over the forecast period. Increasing number of organ transplant procedures along with recurring sales of immunosuppressant drugs is likely to boost the segment growth. For instance, in 2017, there were nearly 90,306 kidney transplant procedures performed worldwide.

End-use Insights

Hospital segment dominated the global transplantation market with value share of approximately 49% in the year 2019 and analyzed to retain its dominance over the forecast period. This is mainly due to increasing number of tissue and organ transplantation at hospitals as they are the primary health treatment centers. In addition, significant advancement along with rising investment for developing hospital Infrastructure equipped with advanced facilities attracts major audience.

On the contrary, transplant centers registered the highest growth rate during the forecast period. Increasing number of transplantations has triggered the need for large number of health centers to cater the patient requirement. Additionally, the rising government initiatives to encourage the public for organ donation again flourish the market growth.

Regional Insights

North America encountered as the most prominent region leading the global transplantation market with significant revenue share of nearly 40% in 2019 and projected to maintain its dominance throughout the analysis period. Well-developed health treatment facilities along with the presence of several major medical devices as well as biotechnologies manufacturing companies such as Zimmer Biomet, Arthrex, Inc., Novartis AG, Medtronic, and Stryker supports the market growth.

However, the Asia Pacific registered the fastest growth over the analysis period due to increasing research activities on stem cells for developing organs and in vitro tissue. Furthermore, developing healthcare infrastructure in various Asian countries such as Thailand, India, Indonesia, and Philippines analyzed to propel the market growth in the region.

Key Companies & Market Share Insights

The global transplantation market is highly fragmented with the presence of several small, medium, and large scale vendors. Major market players focus mainly on mergers & acquisitions, new product launch, and regional expansions to gain significant momentum in terms of revenue share in the industry. Mergers and acquisitions help vendors to expand their geographical reach and existing product portfolio.

Some of the prominent players in the transplantation market include:

• Arthrex, Inc.
• Abbvie, Inc.
• Teva Pharmaceuticals
• Medtronic PLC
• Zimmer Biomet
• Strykers
• Novartis AG
• BiolifeSolutions, Inc.
• 21st Century Medicine
• Veloxis Pharmaceutical

Transplantation Market Size & Market Analysis

Source : https://www.precedenceresearch.com/transplantation-market

The global market for Rheumatoid Arthritis Diagnosis Tests estimated at US$579.8 Million in the year 2020, is projected to reach a revised size of US$766.7 Million by 2026, growing at a CAGR of 4.8% over the analysis period.

Serology Tests, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$561.3 Million by the end of the analysis period.

After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Monitoring Ra Treatment Efficiency Tests segment is readjusted to a revised 4% CAGR for the next 7-year period. This segment currently accounts for a 31.6% share of the global Rheumatoid Arthritis Diagnosis Tests market.

Though the disease can attack at any age its prevalence generally begins in people between 30 to 60 years of age. Females are more two to three times more prone to RA than men. The US had the lowest rate of RA prevalence in the recent past in comparison to the other eight major markets like Australia, the US, Japan, France Italy, Germany, Spain and the UK.

The US had an RA prevalence rate of 67% in comparison with the standard 73% rate in the other eight markets. The UK demonstrated the highest prevalence of RA at 84%. Alterations in the population of the U.S are expected to bring an unprecedented increase in the growth of incidence cases of RA in the U.S. till 2027.

Rheumatoid Arthritis Diagnostics Tests Market Size & Market Analysis

Physicians in the U.S. are expected to focus heavily on diagnostic processes for RA. Rheumatoid arthritis is better managed when detected early as the inflammation reduction process can be begun early. The clinical demonstration of RA is swelling and redness of joints, pain, swelling and stiffness. Diagnosing the disease involves a physical examination, an array of imaging tests, blood tests and medical history analysis of patients and patient`s families.

The diagnosis of RA can be influenced by the challenge of separating the disease from other autoimmune disorders showing similar symptoms. A combination of diagnostic processes including a thorough symptomatic evaluation of the patient, X-ray analysis, blood tests and scans and physical examinations are recommended for the optimal management of this disease.

The U.S. Market is Estimated at $124.3 Million in 2021, While China is Forecast to Reach $113.5 Million by 2026

The Rheumatoid Arthritis Diagnosis Tests market in the U.S. is estimated at US$124.3 Million in the year 2021. The country currently accounts for a 20.66% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$113.5 Million in the year 2026 trailing a CAGR of 6.1% through 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR while Rest of European market (as defined in the study) will reach US$120.4 Million by the close of the analysis period.

Global demographic trends spell opportunities for the rheumatoid arthritis (RA) diagnostic tests market. It is acknowledged that prevalence of RA increases with age, and therefore rising aging population widens the demand for diagnosis tests as well as treatments for RA. Over the course of the next two decades, the proportion of 65+ individuals in the total population is expected to double in countries such as the US, UK and Australia.

With advancing age, the incidence of various health ailments increases, necessitating the need for laboratory tests for diagnosing the specific diseases such as RA. Impact of autoimmune diseases such as RA on quality of life and associated high cost of treatments are prompting governments and healthcare providers to encourage preventive care, especially with focus on aging population.

The growing aging population is therefore offering continuous opportunities for the autoimmune disease diagnostics market, as with advancing age the incidence of various autoimmune conditions such as RA increases, which results in rise in testing volumes translating to higher demand for testing techniques for RA.

As RA is mostly common among the old people, and the geriatric population has been increasing recently, the opportunities in the global rheumatoid arthritis diagnosis test market are expected to be on the rise in the future.

Rheumatoid Arthritis Diagnostics Tests Market Size & Market Analysis

Source : https://www.businesswire.com/news/home/20211008005236/en/Rheumatoid-Arthritis-Diagnosis-Tests-Market—Global-Trajectory-Analytics-to-2026—ResearchAndMarkets.com

The global rheumatoid arthritis drugs market size was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027.

Rheumatoid arthritis is a disease that causes pain and inflammation in joints. It affects individuals of all ages; however, the geriatric population is highly susceptible to develop this disease. The symptoms of rheumatoid arthritis include pain, stiffness, tender, and swelling of joints. Currently, no cure is available for rheumatoid arthritis. However, certain drugs are used to efficiently control the conditions of rheumatoid arthritis, which include disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs. 

Rise in prevalence of rheumatoid arthritis, increase in demand for rheumatoid arthritis drugs, expiration of patents & the entry of biosimilar drugs, surge in geriatric population, increase in adoption of conventional DMARDs, and government initiatives toward spread in awareness for rheumatoid arthritis symptoms are the major factors that drive growth of the rheumatoid arthritis drugs market. In addition, innovations in advanced biologics, rise in healthcare expenditure, improvement in buying power, and access to quality drugs to poor & middle-class families globally are some other factors that contribute toward growth of the market. However, side effects associated with the medication and high costs of biological DMARD therapies are expected to act as the key restraints of the global market. On the contrary, rise in awareness related to early screening and treatment of rheumatoid arthritis is anticipated to offer high growth potential for the rheumatoid arthritis drugs market during the forecast period.

Rheumatoid Arthritis Drugs Market Size & Market Analysis

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. According to the Lancet Rheumatology 2020, patients with rheumatoid arthritis who develop COVID-19 infection may be at high risk for developing severe symptoms and additional complications. Some DMARDs commonly used to treat rheumatoid arthritis, such as hydroxychloroquine drug, are being investigated as potential therapy for COVID-19. Moreover, other generally used therapies such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for manufacturers of rheumatoid arthritis drugs during the forecast period.

Rheumatoid Arthritis Drugs Market Segmentation  

The global rheumatoid arthritis drugs market is segmented into drug class, route of administration, sales channel, and region. Depending on drug class, the market is categorized into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. By route of administration, it is segregated into oral and parenteral. On the basis of sales channel, it is fragmented into prescription-based drugs and over-the-counter drugs. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Presently, on the basis of drug class, the disease-modifying anti-rheumatic drugs (DMARDs) is the major revenue contributor, and is projected to grow significantly during the forecast period. Rise in awareness related to the use of DMARDs, surge in prevalence of rheumatoid arthritis, rise in obese & overweight population across the globe, and increase in adoption of DMARDs as a first-line treatment for rheumatoid arthritis are the key factors that boost growth of the segment.

Depending on sales channel, the prescription-based drugs segment is the major shareholder in the global rheumatoid arthritis drugs market, owing to advantages offered by prescription-based drugs such as patients gets the correct dosage of the drug during the treatment of rheumatoid arthritis, without causing any side effects, and it prevents the potential scope of drug misuse. However, the OTC drugs segment is expected to exhibit the fastest growth rate during the forecast period, owing to convenience of direct purchase and increase in innovations & developments in OTC drugs.

Asia-Pacific presents lucrative opportunities for key players operating in the rheumatoid arthritis drugs market, owing to the presence of large population base susceptible to rheumatoid arthritis, increase in public awareness toward use & benefits of these drugs, development of the R&D sector, rise in healthcare reforms, and increase in adoption of rheumatoid arthritis drugs. Moreover, increase in demand for DMARDs and rise in geriatric population contribute toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high rheumatoid arthritis drugs market share is expected to drive growth of the market in the region.

The key players profiled in this report include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and UCB S.A.

Rheumatoid Arthritis Drugs Market Size & Market Analysis

Source : https://www.alliedmarketresearch.com/rheumatoid-arthritis-RA-drugs-market

The global COPD and asthma diagnostic and monitoring devices market size was accounted for $4,953.60 million in 2019, and is expected to reach $8,202.62 million by 2027, registering a CAGR of 6.3% from 2020 to 2027.

The market for COPD and asthma diagnostic and monitoring devices is experiencing exponential growth due to the COVID-19 pandemic. The COVID-19 is essentially a respiratory ailment has boosted the use of COPD and asthma diagnostic and monitoring devices to monitor the physiological functions of lungs during COVID-19 treatment. This is anticipated to increase the demand of product and drives the market growth in the near future.

The COPD and asthma diagnostic and monitoring devices are used for assessment, diagnosis, and care of patients suffering from lung diseases such as COPD & asthma. As the functioning of lungs deteriorate with growing age, the respiratory system undergoes various physiological, functional, and immunological changes. Rise in incidences of chronic pulmonary diseases and asthma drives the growth of the market. Furthermore, these devices can be used in hospitals and in-home care settings as they have developed from stationary to portable ones.

COPD and Asthma Diagnostic and Monitoring Devices Market Size & Market Analysis

The COPD and asthma diagnostic and monitoring devices market is positively impacted as the spread of Coronavirus (COVID-19) persists throughout the global community. The key market players are supporting the health systems and healthcare professionals actively. For instance, Phillips is providing solutions including invasive and non-invasive ventilation ranging from mid- to high-acuity, patient monitoring, medical consumable, and others. Furthermore, the market for COPD and asthma diagnostic and monitoring devices is experiencing exponential growth due to the COVID-19 pandemic. The fact that COVID-19 is essentially a respiratory ailment has boosted the use of COPD and asthma diagnostic and monitoring devices to monitor the physiological functions of lungs during COVID-19 treatment. This is anticipated to increase the demand of product and drives the COPD and asthma diagnostic and monitoring devices market growth in the near future.

Moreover, air pollution, climate changes, and allergies are further driving the market growth. The development of technologically advanced devices, regulatory approvals, and product launches drives the market growth. However, high costs of the device and stringent regulatory procedures impede the market growth. Moreover, increase in initiatives taken by authorities and governments to improve healthcare systems and spread awareness regarding benefits of COPD and asthma diagnostic and monitoring devices are also expected to drive the growth of the global COPD and asthma diagnostic and monitoring devices market.

Rise in lifestyle habits such as smoking, consumption of alcohol, and an increase in the geriatric population is a significant factor boosting the market. Technological advances for new devices, regulatory approvals, and product launches are further promoting the market growth. The prevalence of air pollution, climate changes, and dust is also fueling the market growth. Moreover, rise in prevalence of respiratory diseases is increasing globally. In 2017, according to the WHO, respiratory diseases were considered to be the leading causes of death and disability in the world. Nearly 65 million people suffer from COPD, and 3 million are expected to die from it each year, making it the third leading cause of death across the world. Moreover, approximately 334 million people suffer from asthma, the most common chronic disease of childhood, affecting 14% of all children globally. On the contrary, surge in number of regulations promote use of COPD and asthma diagnostic and monitoring devices and increase in funds for research in developing countries are expected to offer lucrative opportunities for the market in the future.

Copd And Asthma Diagnostic And Monitoring Devices Market Segmentation

The global COPD and asthma devices market is segmented on the basis of product, indication, end user, and region. Based on the product, the market is segmented into diagnostic devices, monitoring devices, and consumables and accessories. Furthermore, the diagnostic devices segment includes spirometers electrocardiogram, FeNo test analyzer, peak flow meter, arterial blood gas analyzer (ABG), polysomnography devices, and others. The monitoring devices segment includes pulse oximeters, capnograph, asthma monitors, portable table top pulse oximeter, wearable devices, Fourier transform infrared spectroscopy (FTIR), others. The consumables and accessories segment includes masks, spirometry accessories, polysomnography accessories, peak flow meter accessories, pulse oximeter sensors, capnography accessories, gas analyzer accessories, and others. Based on indication, the market is divided into asthma and COPD. Based on end user, it is segregated into hospitals & clinics, home care settings, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

On the basis of product type, the diagnostic devices segment is expected to maintain its dominant position throughout the forecast period. This is attributed to increase in investment by the giant players and increase in research related funding made it convenient to use them, which further made them portable and automatic. All these factors are expected to propel growth of the COPD and asthma diagnostic and monitoring devices market during the forecast period. In addition, by indication, the asthma segment dominated the market in 2019, owing to rise in prevalence of asthma patients across the globe.

By end user, the hospitals & clinics segment is expected to grow at the highest CAGR during the forecast period. This is attributed to rise in number of patients diagnosed with respiratory diseases, increase in government initiatives, and technological upgradation in COPD & asthma devices.

• Key Market Segments By Product
  • Diagnostic Devices
    • Spirometers
    • Electrocardiogram
    • FeNo Test Analyzer
    • Peak Flow Meter
    • Others
  • Monitoring Devices
    • Pulse Oximeters
    • Capnograph
    • Asthma Monitors
    • Portable Table Top Pulse Oximeter
    • Wearable devices
    • Fourier Transform Infrared Spectroscopy (FTIR)
    • Others
  • Consumables and Accessories
    • Masks
    • Spirometry Accessories
    • Polysomnography Accessories
    • Peak Flow Meter Accessories
    • Pulse oximeter sensors
    • Capnography Accessories
    • Gas Analyzer Accessories
    • Others

COPD and Asthma Diagnostic and Monitoring Devices Market Size & Market Analysis

Registering a CAGR of 8.8% over the forecast period of 2022-2027, the global Pancreatic Cancer Diagnostic market is anticipated to reach the market value of US$ 6224 million in the year 2027 from US$ 3865 million in the year 2021.

Pancreatic Cancer Diagnostics Market Size & Market Analysis

Pancreatic cancer arises when there is an uncontrollable growth of cells in the pancreas. Pancreatic cancer is categorized as exocrine and endocrine, based on the cells affected by cancer. Exocrine cells in the pancreas generate pancreatic enzymes. When cancer manifests in these cells, it is referred to as exocrine pancreatic cancer. Endocrine cells are a small cluster of cells and are also called islets of Langerhans. These cells create hormones, such as insulin and glucagon, releasing them into the blood flow.

Chemotherapy is one of the main cancer treatments that kill pancreatic cancer cells by preventing them from growing and dividing. These drugs are systemic treatments; the drugs travel through the bloodstream and damage cancer cells throughout the body. Unfortunately, chemotherapy can damage some healthy cells and cause major side effects. Chemotherapy may shrink and/or prevent the growth of pancreatic tumors. Factors such as the increasing prevalence and incidence of pancreatic cancer and advancements in molecular biology, development of drugs, and diagnostic technology play a major part in market growth. With the increase in R&D initiatives, favorable reimbursement scenarios, and the launch of novel products, the market is expected to grow significantly during the forecast period.

Who are the Major Players in Pancreatic Cancer Diagnostic Market?

The global Pancreatic Cancer Diagnostic includes the identification and analysis of the various market participants competing in the global market. Prominent competitors include Siemens, GE Healthcare Inc. (Other OTC:GENN), Roche Holding AG (Other OTC :RHHBY), Philips Healthcare, Danaher Corporation (NYSE :DHR), Canon Medical Systems, Abbott Laboratories (NYSE:ABT), Hitachi Medical, Qiagen N.V. (NYSE:QGEN), Apexigen Inc., Myriad Genetics,Inc. (NasdaqGS:MYGN)and Others.

What are the major Applications, Types and Regions for Pancreatic Cancer Diagnostic Market?

By Type, it is segmented into

• Imaging
• Tumor Biomarker
• Biopsy

By Application, it is segmented into

• Hospitals
• Clinics

Pancreatic Cancer Diagnostic Market Regional Analysis

The United States is anticipated to retain its significant market share due to the rising incidence of pancreatic cancers, supportive reimbursement policies, and high healthcare spending.

As per a 2018 publication in the MedCrave Gastroenterology and Hepatology journal, pancreatic cancer was the ninth most frequent cancer, despite its moderate incidence. It was estimated to be among the second-deadliest cause of cancer by 2027. Also, according to the GLOBOCAN 2020 report, about 56,734 new cases of pancreatic cancer were reported in 2020.

Pancreatic Cancer Diagnostics Market Size & Market Analysis

Source :https://www.industrydataanalytics.com/reports/pancreatic-cancer-diagnostic-market

Artificial Intelligence in Radiology Market is valued at USD 53.9 Million in 2021 and expected to reach USD 461.1 Million by 2028 with a CAGR of 35.9% over the forecast period.

Increasing adoption of new technologies and smart solutions with the help of artificial intelligence is the next revolution in patient care driving the market growth.

Artificial intelligence also known as machine intelligence is a branch of computer science that works to create intelligent machines. The use of artificial intelligence has been rapidly progressing in medicine, particularly in radiology. In radiology, it is used to identify the onset of diseases at early stage and enable to plan the treatment for long term needs and offer the highest level of accuracy. AI is used in medical field as clinical decision support and information management (for both physician as well as patients) and can modify the practice of radiology in processes such as detection & prioritization, monitoring & registration, image acquisition and reporting. This technology can be used to analyze medical imaging solutions to identify most effective solution for acute abnormalities across both human as well as animal bodies. It can add a layer of precision and consistency to the search for anomalies if something goes unnoticed. Time sensitive cases like stroke treatments can be diagnosed faster by operating AI systems. The challenges in this field now become identifying opportunities for reducing inefficiencies in radiology workflow through AI integration.

Artificial Intelligence In Radiology Market Size & Market Analysis

Artificial intelligence in radiology market report is segmented on the basis of radiology type, application, technique and region & country level. Based upon radiology type, artificial intelligence in radiology market is segmented into mammography, chest imaging, neurology, colonography, cardiovascular, head CT scan and rest of the body. Based on application, the market is segmented into computer-aided diagnosis, clinical decision support, quantitative analysis tools, and computer-aided detection. Based upon technique, artificial intelligence in radiology market is segmented into x-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, potential emission tomography (PET) and others.

The regions covered in this artificial intelligence in radiology market report are North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. On the basis of country level, the market of artificial intelligence in radiology is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

Artificial Intelligence In Radiology Market Dynamics-

The artificial intelligence in radiology market is driven by the factors such as use of machine learning technology in diagnostic imaging along with the increasing use of quantitative imaging and biomarkers imaging in clinical practices. Apart from making radiologists more productive and efficient, AI and machine learning are likely to improve the experience of patients throughout imaging process. Market players are coming up with new image acquisition hardware along with embedded AI technologies. Core structure such as computing and storage devices, networking has also improved in performance with current technical advancements. Additionally, increase in the use of AI beyond image analysis like practice management, quality assurance and improvements in the performance of deep learning algorithms over early generation of AI are the factors that are also supporting the market growth. However, the factors such as slow regulatory approval process, lack of real-world confirmation to validate the economic benefits and the return on investment, and long sales & implementation cycles may hamper the market growth.

Moreover, offering speed, accuracy and quality of image interpretation and diagnosis in radiology creating new revenue opportunities for the market. Also, advances in computing and rapid changes in medical industry accelerating the innovations and huge R&D developments are fuelling the future growth of the market.

Regional Analysis

The artificial intelligence in radiology market by region is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. North America has captured the largest market share and is expected to continue the same over the forecast period owing to the well-established healthcare and medicine systems that supports the use of new technologies in this region. Startups receiving the most investors’ attention in AI due to which the market in North America is anticipated to observe high growth. The national institutes of health (NIH) held a workshop to explore the future of AI in medical imaging in which they found imaging research laboratories are swiftly generating machine learning systems that achieve expert human performance using open source methods and tools shows R&D developments in North America. Asia-Pacific countries are expected to show fast growth in the forthcoming years because of the growing technologies in imaging and biotechnology sectors and Government initiatives & increasing healthcare expenditures. In addition to this, presence of large number of patients and population pool will foster the market growth in this region within the forecast period. Based on the size of its population and huge volume of accessible digital medical data, china has significant advantage in developing medical AI and thus emerging as a popular hub for healthcare AI in radiology.

Artificial Intelligence In Radiology Market Segmentations:

Radiology Types:

• Mammography
• Chest Imaging
• Neurology
• Colonography
• Cardiovascular
• Head CT Scan
• Rest of the body

Applications:

• Computer-aided Diagnosis
• Clinical Decision Support
• Quantitative Analysis Tools
• Computer-aided Detection

Techniques:

• X-rays
• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Ultrasound
• Positron Emission Tomography (PET)
• Others

Artificial Intelligence In Radiology Market Size & Market Analysis

Source : https://brandessenceresearch.com/healthcare/artificial-intelligence-in-radiology

The global AI in medical imaging market is projected to cross USD 10 billion by 2027, growing at a CAGR of 45% from USD 1.06 billion in 2021. AI in medical imaging has shown impressive accuracy and sensitivity in identifying abnormalities and promises to enhance tissue-based detection and characterization. One of the most promising areas of health innovation is the application of artificial intelligence (AI), mainly in medical imaging.

The constant increase in the number of diagnostic procedures and the decline in the number of radiologists, increasing work pressure on the radiologists, have increased the need for artificial intelligence adoption in the medical imaging space. The researchers are looking for multiple ways to implement artificial intelligence into medical imaging. The demand for artificial intelligence is constantly increasing in the medical imaging software market. From cardiac events, neurological conditions, fractures, or thoracic complications, artificial intelligence helps physicians to diagnose and provide treatment quickly. Implementing AI in medical imaging has enhanced medical screening, improved precision medicine software, reduced physicians’ load, etc.

Technological Advancements Revolutionizing AI in Medical Imaging

• There have been many technological advancements in AI-based medical imaging technologies, which have shown their increasing acceptance in high-income countries. Some of the improvements include the development of integrated rtiI software, which can directly be integrated into imaging equipment (MRI or CT scanner) which facilitates the automation of medical image analysis. Other advances include smartphone technology integration in AI in medical imaging in which front-line health workers could non-invasively screen for various conditions by leveraging a smartphone.
• AI in medical imaging has drawn the attention of several radiologists worldwide. It gives faster and more accurate results and reduces diagnostic errors at reduced costs compared to traditional medical imaging methods. Thus, radiologists believe that AI in medical imaging may bring an enormous opportunity for its increasing implementation in the upcoming years.
• In recent years, many large established companies, such as GE Healthcare and Siemens Healthineers, have enabled themselves to grow the AI in the medical imaging market by making huge investments for increasing partnerships and acquisitions. Other large healthcare-related or software companies not previously invested in health care, such as Thermo Fisher Scientific and Paraxel, have started making huge investments in the market.

Vendor’s Activity in AI-Based Medical Imaging Market

Siemens Healthineers, General Electric (GE) Company, Koninklijke Philips, and IBM Watson Health are the major players in the global AI in the medical imaging market. International players focus on developing innovative products with advanced technologies and expanding their product portfolio to remain competitive. They are continuously investing extensively in R&D to expand their product portfolio. Manufacturers such as GE Healthcare constantly focus on introducing new products with innovative technology platforms opening the platform (Edison Developer Program) for other companies offering artificial intelligence technologies to scale and deploy their developed applications across GE Healthcare’s customer base.

Many major players are engaged in strategic acquisitions and partnerships that continue to be a competitive strategy for the key players, thus helping them grow inorganically. Innovative product approvals coupled with R&D activities are also helping the vendors to expand their presence, enhance growth, and sustain their position in the global market. In 2021, more than 30 countries approved AI in medical imaging technologies that are FDA and CE approved.

There is increasing funding and investments by public and private entities, including large companies, which is also one of the major driving factors of AI in the medical imaging market. For instance, more than 20 start-ups from various regions have received funds to develop AI-based medical imaging technologies.

GEOGRAPHY INSIGHTS

• North America holds a dominant position in artificial intelligence in the medical imaging market. High adoption of advanced technologies is the primary factor for its larger industry share. In addition, the strong presence of the key players in the region is also a contributor to North America for holding a high market share.
• Europe is the second-largest market for AI-based medical imaging. The presence of prominent market players and high healthcare spending are the primary factors for the significant market share in this region. The industry in Europe is mainly driven by the increasing collaborative research with extensive funding from the government. Increasing funding and investments are also driving the AI-based medical imaging market in the region.
• The adoption rate of advanced artificial intelligence technologies in the medical imaging sector is still emerging in the Asia-pacific region. In recent years, there has been a noticeable investment and funding made by government and corporations and increasing collaborations and partnerships among the companies, research centers, and institutes. Due to these factors, the industry is growing exponentially in this region.
• Lack of awareness of the importance of artificial intelligence in medical imaging, radiologists’ job insecurity, a lack of sufficient IT infrastructure, a lack of proper training and knowledge among radiologists, concerns about data security, and a shortage of skilled professionals are all factors contributing to the industry’s slow growth in Latin America, the Middle East, and Africa.
• Among all the regions, APAC could witness the highest growth over the forecast period, with a CAGR of 51.06% in the global industry. The increasing prevalence of chronic diseases and diagnostic errors has opened enormous opportunities for APAC medical imaging AI market growth.

SEGMENTATION ANALYSIS

Hospitals are purchasing the artificial intelligence medical software suits as a complete package for the usage or taking up one program at a time which is used the most in the industry. The diagnostic imaging center’s significant revenue generation is through imaging procedures, and they are primarily involved in implementing advanced products, which will attract customers. For instance, AI in medical imaging, along with clinical data, is helping physicians to predict heart attacks in patients accurately.

Neurology has accounted for the dominating share in the industry. The majority of the initial artificial intelligence product development focuses on downstream processing. This Downstream processing majorly includes artificial intelligence for segmentation, detecting anatomical structures, and quantifying a range of pathologies. Conditions like intracranial hemorrhage, ischemic stroke, primary brain tumors, cerebral metastases, and abnormal white matter signal intensities, which were unmet needs in the industry, has become commercially available solution within the radiology industry.

AI in medical imaging, especially cardiovascular magnetic resonance (CMR), is revolutionized by providing deep learning solutions, especially for image acquisitions, reconstructions, and analysis, which helps in supporting clinical decision-making. CMR is an established tool for routine clinical decision-making, including diagnosis, follow-up, real-time procedures, and pre-procedure planning.

Artificial Intelligence in Medical Imaging Market Size & Market Analysis

Deep learning methods have enabled more tremendous success in medical image analysis. They have helped high accuracy, efficiency, stability, and scalability. Artificial intelligence tools have become assistive tools in medicine with benefits like error reduction, accuracy, fast computing, and better diagnostics. Natural language processing, Computer Vision, and Context-Aware Computing technologies are also used to create new analysis methods for medical imaging products.

In 2021, Philips showcased its new AI-enabled CT imaging portfolio. Their new CT 5100 with smart workflow application applies artificial intelligence at every step of CT image processing.

Siemens Healthineers’s AI-Rad companion chest CT detects and highlights lung nodules. The tumor burden is automatically calculated. In addition, AI-Rad companion chest X-Ray played a significant role in patient management during the COVID-19 pandemic. The artificial intelligence-Rad companion file automatically processes upright chest X-ray images, pneumothorax, nodule detection, etc. This indicates the consolidations and atelectasis. This indicates the sign of pneumonia caused by the COVID-19 virus.

Artificial intelligence in CT scans and MRI dominated the industry, as much medical imaging using artificial intelligence tools falls into these modality categories. However, artificial intelligence in ultrasound and detecting mammography is largely adopted in the industry.

Artificial Intelligence in Medical Imaging Market Size & Market Analysis

Source : https://www.arizton.com/market-reports/artificial-intelligence-in-medical-imaging-market

The asthma drugs market is projected to reach US$ 34,136.10 million in 2028 from US$ 24,239.17 million in 2021; it is estimated to grow at a CAGR of 5.0 % during 2021-2028.

The asthma drug market growth is attributed to the growing environmental implications & genetic implications of air pollution, more vulnerability in specific ethnic groups, growing exposure to coarse particulate matters, and growing prevalence of physiological disorders harboring asthma. However, unmet medical needs and lack of treatment adherence hamper the asthma drug market growth.

Asthma is a chronic respiratory condition marked by fluctuating airflow restriction, bronchial hyperresponsiveness, and airways inflammation. According to a review paper titled “Impact of Air Pollution on Asthma Outcomes” by Tiotiu et.al., air pollution hampered asthma outcomes in adults and children. Air pollution from traffic, nitrogen dioxide (NO2), and second hand smoking (SHS) are all substantial risk factors for the development of asthma in children. Asthma symptoms, exacerbations, and decreased lung function can be triggered by exposure to outside pollution.

Asthma Drugs Market Size Market Analysis

In the US, exposure to air pollution continues to be associated with asthma. This severe and life-threatening chronic respiratory condition impacts the quality of life of more than ~23 million American citizens. Air pollution can aggravate asthma symptoms, triggering asthma attacks among people. Children with asthma, which affects ~6 million children in the US, are particularly vulnerable to pollution.

A new study financed by the Environmental Protection Agency (EPA) analyzed the link between air pollution and asthma. While experts cannot determine the primary asthma-causing agent due to air pollution, evidence suggests that it suppresses genes that control the immune system to distinguish between an allergen and a hazardous foreign substance, such as a virus or bacteria. The immune system then goes into overdrive, triggering an inflammatory reaction regardless of whether the drug is toxic, resulting in asthma.

Researchers from Stanford University’s Children’s Center investigated the effect of air pollution on two genes involved in immunological tolerance in children from an area with high levels of pollution. They discovered that short- and long-term exposure to high amounts of carbon monoxide (CO), NO2, and particulate matter) (PM2.5) were linked to changes in these two genes, which caused asthma. These findings focused on the epigenetic impacts of air pollution exposure and could help develop preventative asthma medicines.

Each of these asthma research improved the understanding of asthma in children and supplied crucial information to the EPA that can be used to protect human health and the environment. Through these research works, the drug discovery and development for asthma is being expedited, which is driving the asthma drug market.

The COVID-19 crisis created a public health and economic crisis in many countries worldwide. The pandemic adversely affected a large percentage of the population in the first half of 2020. With the virus affecting the respiratory system primarily, individuals with respiratory disorders were at a considerably higher risk of mortality and complications. For this, various organizations such as the Centers for Disease Control & Prevention, Asthma & Allergy Foundation of America, the World Health Organization, and the European Respiratory Society published guidelines, standards, and norms for patient care, differentiation of COVID-19 from other flu-like diseases, asthma, and allergies, and steps to avoid contracting COVID-19 in an asthmatic patient.

Various recommendations were also released, such as stocking up on asthma drugs to prevent the shortage of drugs for asthmatic patients. Various organizations, such as the WHO, concluded that the risk of infection was higher in people with asthma, leading to further exacerbation of asthma. The WHO also mentions that people with asthma who appear more vulnerable to worse outcomes included those who also had chronic obstructive pulmonary disease and people with non-allergic asthma compared to allergic asthma. Older age and non-white ethnicity also appear to confer greater risk, as expected from data from the general population.

Market Dynamics

Drivers

• Growing Environmental Implications & Genetic Implications of Air Pollution
• More Vulnerability in Specific Ethnic Groups
• Growing Exposure to Coarse Particulate Matters
• Growing Prevalence of Physiological Disorders Harboring Asthma

Restraints

• Unmet Medical Needs
• Lack of Treatment Adherence

Opportunities

• Opportunities with Commercialization of Biologics
• Future Trends
• Increasing Research Activities and Product Innovations

Main Players :

• AstraZeneca
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Merck & Co. Inc.
• Koninklijke Philips NV
• Sanofi
• Pfizer Inc.
• Novartis AG
• Abbott

Asthma Drugs Market Size Market Analysis

Source :  https://www.researchandmarkets.com/reports/5598073/global-asthma-drugs-market-forecast-to-2028

The global antibodies contract manufacturing market is expected to reach from USD 13.4 billion in 2022 to USD 35.9 billion by 2030, registering a CAGR of 13.1% from 2022 to 2030.

Rise in demand for the production of therapeutic antibodies is the main factor that will drive the growth of the market during the forecast period. Antibodies are the leading biopharmaceutical products that precisely target abnormal cells.

Thus, many biopharmaceutical companies have begun to focus on the development of advanced antibodies for the treatment of chronic diseases such as cancer, arthritis, and rheumatic heart disease. The impact of COVID-19 has boosted the market growth, with the application of monoclonal antibodies therapy used as a treatment for COVID-19 patients.

A surge in the R&D budget for the production of antibodies by key players is also driving the growth of the market. For the ongoing fight against COVID-19, Monoclonal antibody (mAb) therapy is proven to be an effective treatment. The aim of this treatment is to prevent hospitalizations, decrease viral loads, and minimize symptom severity.

During the coronavirus outburst, the supply chain of biopharmaceutical companies remained robust and was largely unaffected worldwide. Similarly, antibody contract manufacturers are observing a rise in demand for the production of antibodies that will be used for treatments related to the COVID-19 vaccine and therapeutics.

Thus, the future holds numerous opportunities for the antibody contract manufacturing market. For instance, in December 2021, an agreement was formed between Samsung Biologics and AstraZeneca to manufacture Evusheld, which is an amalgamation of binary antibodies in development for the potential treatment of COVID-19.

The growth of CMOs is greatly dependent on favorable opportunities offered by the biopharmaceutical industry. Expansion and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market.

For instance, in 2022, FUJIFILM Diosynth Biotechnologies announced an expansion in North Carolina; with this expansion, the company will increase skilled positions including researchers and scientists by 2024 to generate strong commercial processes.

Monoclonal antibodies-based antibody contract manufacturing captured the largest market share about 70.9% in 2021, owing to the high penetration of mammalian expression systems for biologics development.

Based on the source offered in this market, the mammalian segment contributed the largest share of 58.5% in 2021, as they are considered a more reliable, robust, and relatively mature technology.

Asia Pacific is expected to emerge as the fastest-growing regional market with a CAGR of 13.3% from 2022 to 2030, owing to developing economies such as India, South Korea, and China incorporating developments to sustain the competition.

Antibodies Contract Manufacturing Market Size and Market Analysis

Source : https://www.researchandmarkets.com/reports/5595846/antibodies-contract-manufacturing-market-size

The global Artificial Intelligence in Drug Discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period.

The growth of this Artificial Intelligence in Drug Discovery Market is driven by the growing need to control drug discovery & development costs, and growing number of cross-industry collaborations and partnerships, On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

Services segment is expected to grow at the highest rate during the forecast period.

Based on offering, the AI in drug discovery market is segmented into software and services. In 2021, the services segment accounted for the largest market share of the global AI in drug discovery services market and also expected to grow at the highest CAGR during the forecast period. The benefits associated with AI services and the strong demand for AI services among end users are the key factors driving the growth of this market segment.

Machine learning technology segment accounted for the largest share of the global AI in drug discovery market.

Based on technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. The machine learning technology segment further segmented into deep learning, supervised learning. reinforcement learning, unsupervised learning, and other machine learning technologies. Deep learning segment accounted for the largest share of the market in 2021, and this segment also expected to grow at the highest CAGR during the forecast period.

The immuno-oncology application segment accounted for the largest share of the AI in drug discovery market in 2021.

On the basis of application, the AI in drug discovery market is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular diseases, metabolic diseases, and other applications. The immuno-oncology segment accounted for the largest share of the market in 2021, owing to the increasing demand for effective cancer drugs. The neurodegenerative diseases segment is estimated to register the highest CAGR during the forecast period. The role of AI in resolving existing complexities in neurological drug development and strategic collaborations between pharmaceutical companies & solution providers are the key factors responsible for the high growth rate of the neurodegenerative diseases segment.

Pharmaceutical & biotechnology companies segment accounted for the largest share of the global AI in drug discovery market.

On the basis of end user, the AI in drug discovery market is segmented into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. The pharmaceutical & biotechnology companies segment accounted for the largest market share of AI in drug discovery market, in 2021, while the research centers and academic & government institutes segment is projected to register the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is driving the growth of this end-user segment.

North America is expected to dominate the Artificial Intelligence in Drug Discovery Market in 2022.

North America accounted for the largest share of the global AI in drug discovery market in 2021 and also expected to grow at the highest CAGR during the forecast period. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the key factors responsible for the large share and high growth rate of this market

Prominent players in this Artificial Intelligence in Drug Discovery Market are NVIDIA Corporation (US), Microsoft Corporation (US), Google (US), Exscientia (UK), Schrödinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), BERG LLC (US), Cloud Pharmaceuticals (US), Insilico Medicine (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), Owkin, Inc. (US), XtalPi (US), Verge Genomics (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Source : https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html